title: Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma.
abstract: BACKGROUND
  Cisplatin-based induction chemotherapy before surgery or irradiation has improved the survival of patients with Stage III nonsmall cell lung carcinoma (NSCLC). Encouraged by earlier results with preoperative MVP (cisplatin [120 mg/m(2) or 25 mg/m(2)/week], vinblastine, and mitomycin) for Stage IIIA patients with clinically apparent mediastinal (N2) disease, the authors conducted a Phase II trial of the safety and efficacy of induction MVP400 with the dose intensity of cisplatin doubled from 25 to 50 mg/m(2) per week.
  
  
  METHODS
  From October 1992 to March 1996, 37 patients with Stage IIIA (26) or Stage IIIB (11) NSCLC began the MVP400 induction chemotherapy program. Four doses of cisplatin (100 mg/m(2)), 7 doses of vinblastine, and 2 doses of mitomycin were given over 9 weeks. Patients received either surgery or irradiation after induction treatment.
  
  
  RESULTS
  Overall, the response rate was 65% (95% confidence interval, 49-81%) with a complete resection rate of 67%. The median survival was 17 months, with 66% of patients alive at 1 year. Complete resection and Stage IIIA involvement were favorable prognostic indicators for survival. No Stage IIIB patients underwent a complete resection. Myelosuppression was the most common side effect. There were no treatment-related deaths.
  
  
  CONCLUSIONS
  Although high response and complete resection rates were again demonstrated, results with the MVP400 regimen were not improved over those achieved with MVP regimen tested earlier with Stage IIIA (N2) patients. The authors continue to recommend MVP as an induction chemotherapy regimen for clinical trials.
authors.affiliation: Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York 10021, USA.
authors.forename: K K
authors.initials: KK
authors.lastname: Ng
authors.forename: M G
authors.initials: MG
authors.lastname: Kris
authors.forename: R J
authors.initials: RJ
authors.lastname: Ginsberg
authors.forename: R T
authors.initials: RT
authors.lastname: Heelan
authors.forename: K M
authors.initials: KM
authors.lastname: Pisters
authors.forename: V A
authors.initials: VA
authors.lastname: Miller
authors.forename: S C
authors.initials: SC
authors.lastname: Grant
authors.forename: M
authors.initials: M
authors.lastname: Bains
authors.forename: V
authors.initials: V
authors.lastname: Rusch
authors.forename: K E
authors.initials: KE
authors.lastname: Rosenzweig
authors.forename: N
authors.initials: N
authors.lastname: Martini
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000633:toxicity; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000633:toxicity; D008937:Mitomycins / Q000008:administration & dosage; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage / Q000633:toxicity
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D014747:Vinblastine; D002945:Cisplatin; D014751:Vindesine